Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms. Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I clinical trial for the treatment of cardiovascular, pulmonary diseases, pulmonary hypertension, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System. Cereno Scientific AB (publ) was incorporated in 2012 and is headquartered in Gothenburg, Sweden.
Часто задаваемые вопросы
В каком секторе работает Cereno Scientific AB Series B (CRNO-B)?
Cereno Scientific AB Series B относится к сектору Здравоохранение.
Какова текущая цена акций Cereno Scientific AB Series B (CRNO-B)?
По последним данным, цена акций Cereno Scientific AB Series B составляет 4,12 SEK, предыдущее закрытие — 4,08 SEK. За последнюю торговую сессию акции Cereno Scientific AB Series B выросли на 0,04 SEK, что соответствует росту на 0,93%.
Выплачивает ли Cereno Scientific AB Series B (CRNO-B) дивиденды?
Нет, Cereno Scientific AB Series B не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Cereno Scientific AB Series B (CRNO-B)?
У компании Cereno Scientific AB Series B бета -0.385, что указывает на более низкую волатильность по сравнению с рынком в целом.
